Juno Therapeutics, a subsidiary of Bristol Myers (BMY) Squibb, was granted FDA orphan designation for its treatment of systemic sclerosis, according to a post to the agency’s website.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
- Top drugmakers to enter agreements with U.S. to cut drug prices, Reuters says
- BMY and BNTX Advance New Immunotherapy Bet in First-Line Liver Cancer With ROSETTA HCC-206
- Cytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding
- Bristol-Myers Squibb to Launch Phase 3 Trial for Schizophrenia Drug KarXT in Adolescents